[go: up one dir, main page]

MX2018010223A - Terapia combinada para tratamiento de cancer de ovario. - Google Patents

Terapia combinada para tratamiento de cancer de ovario.

Info

Publication number
MX2018010223A
MX2018010223A MX2018010223A MX2018010223A MX2018010223A MX 2018010223 A MX2018010223 A MX 2018010223A MX 2018010223 A MX2018010223 A MX 2018010223A MX 2018010223 A MX2018010223 A MX 2018010223A MX 2018010223 A MX2018010223 A MX 2018010223A
Authority
MX
Mexico
Prior art keywords
ovarian cancer
treatment
combination therapy
patient
effective amount
Prior art date
Application number
MX2018010223A
Other languages
English (en)
Inventor
Proia David
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of MX2018010223A publication Critical patent/MX2018010223A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se relaciona con métodos para tratar a un paciente con cáncer de ovario que tiene deficiencias en la recombinación homóloga (HR), que comprende administrar al paciente: (i) una cantidad efectiva de ganetespib, o una sal farmacéuticamente aceptable del mismo; y (ii) una cantidad efectiva de un agente que daña el ADN o inhibe la reparación.
MX2018010223A 2016-02-29 2017-02-28 Terapia combinada para tratamiento de cancer de ovario. MX2018010223A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301225P 2016-02-29 2016-02-29
PCT/US2017/019843 WO2017151554A1 (en) 2016-02-29 2017-02-28 Combination therapy for treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
MX2018010223A true MX2018010223A (es) 2018-11-09

Family

ID=59744380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010223A MX2018010223A (es) 2016-02-29 2017-02-28 Terapia combinada para tratamiento de cancer de ovario.

Country Status (9)

Country Link
US (1) US11154538B2 (es)
EP (1) EP3423048A4 (es)
JP (3) JP2019508429A (es)
CN (1) CN108697666A (es)
AU (2) AU2017227534A1 (es)
CA (1) CA3014680A1 (es)
IL (1) IL261195B (es)
MX (1) MX2018010223A (es)
WO (1) WO2017151554A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7083760B2 (ja) * 2016-06-29 2022-06-13 テサロ， インコーポレイテッド 卵巣癌の治療方法
CA3084988A1 (en) * 2017-12-29 2019-07-04 Vertex Pharmaceuticals Incorporated Methods of cancer treatment using an atr inhibitor
EP3737416A4 (en) 2018-01-12 2022-03-30 Prolynx LLC PROTOCOL FOR MINIMIZING TOXICITY OF DOSAGE COMBINATIONS AND IMAGING AGENT FOR VERIFICATION
EP3966782A2 (en) 2019-05-06 2022-03-16 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN113462784B (zh) * 2021-08-31 2021-12-10 迈杰转化医学研究(苏州)有限公司 一种构建用于同源重组修复缺陷检测的靶标集合的方法
JPWO2023157891A1 (es) 2022-02-16 2023-08-24
TW202434243A (zh) * 2022-11-21 2024-09-01 日商富士軟片股份有限公司 含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥
CN116024162B (zh) * 2023-02-27 2025-01-10 山东大学 Egcg联合chk2抑制剂在改善卵成熟或胚胎发育中的应用
WO2024249756A1 (en) * 2023-06-02 2024-12-05 Zeno Management, Inc. Homologous recombination repair deficiency (hrd) as a predictive biomarker for treating cancer with wee1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007005940A (es) 2004-11-18 2007-06-19 Synta Pharmaceuticals Corp Compuestos de triazol que modulan la actividad hsp90.
EP2217244A4 (en) * 2007-11-12 2011-08-31 Bipar Sciences Inc TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
US20140315943A1 (en) * 2011-05-24 2014-10-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2714033A1 (en) 2011-05-26 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
EP2773345A1 (en) * 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2014138101A1 (en) * 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
JP6114075B2 (ja) * 2013-03-07 2017-04-12 三菱航空機株式会社 航空機の警報システム、及び、航空機
CA2912830A1 (en) * 2013-05-21 2014-11-27 Synta Pharmaceuticals Corp. Specific cancer treatment regimens with ganetespib
PT3180447T (pt) 2014-08-15 2020-06-18 Myriad Genetics Inc Métodos e materiais para avaliar a deficiência de recombinação homóloga

Also Published As

Publication number Publication date
CN108697666A (zh) 2018-10-23
EP3423048A1 (en) 2019-01-09
US20190060285A1 (en) 2019-02-28
CA3014680A1 (en) 2017-09-08
IL261195A (en) 2018-10-31
AU2017227534A1 (en) 2018-08-30
JP2022079569A (ja) 2022-05-26
JP2019508429A (ja) 2019-03-28
US11154538B2 (en) 2021-10-26
AU2023200554A1 (en) 2023-03-02
WO2017151554A1 (en) 2017-09-08
JP2024054312A (ja) 2024-04-16
EP3423048A4 (en) 2019-10-23
IL261195B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
SG10201902664RA (en) Combination therapy for treating cancer
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2020001727A (es) Terapia de combinacion.
PH12016502352A1 (en) Pharmaceutical composition
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2019013862A (es) Terapia de combinacion.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.